AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 281 min read$NMTC

NeuroOne Medical (NMTC) CEO granted 68K stock options

NeuroOne Medical (NMTC) CEO David A. Rosa received a grant of 68,000 stock options. The options have an exercise price of $1.77 per share, expire in 2036, and vest over time, with 25% vesting in 2027 and the remainder in quarterly installments.

Original reporting
stocktitan.net
Published Aug 28, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 6:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NMTC
Neutral
high confidence
Mentioned
$NMTC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$NMTCNeutralLow
01

Why it matters

The grant is a routine compensation event with limited market impact.

02

Market read

Low relevance; the filing provides a minor data point for insiders but is unlikely to move the stock.

03

What to watch

Potential future dilution if options are exercised and the stock price rises above $1.77.

Relevance 4/10Novelty 3/10Timing: filing date Aug 28, 2026

Background

Form 4 filing discloses insider compensation; NeuroOne Medical Technologies Corp is a micro‑cap listed on Nasdaq under NMTC.

Company-level read

Ticker impact

$NMTCNeutralHigh confidence
Context

CEO David A. Rosa received a grant of 68,000 stock options with $1.77 exercise price, vesting starting Aug 28, 2027.

Expected impact

Minimal, likely negligible effect on share price.

Evidence & confidence

The grant size is modest for a micro‑cap and the exercise price is near current market levels, so no material upside or downside is expected.

Market effects

Sector

None; the grant does not affect the broader medical device sector.

Regional

Limited to the company's existing shareholder base.

Global

None

Counterpoint

What could challenge this read

Even small insider grants can signal confidence; some traders may view it as a subtle bullish cue.

Key entities

  • person
    David A. Rosa

    CEO & President of NeuroOne Medical Technologies Corp.

Read at source← All news

Related articles

OCT 5
$NMTCLow

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

SEC EDGAR 8-K1 min
AUG 27
$NMTCMed

EQS-News: NeuroOne Medical Technologies: NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED Platform

NeuroOne Medical Technologies (NMTC) reported successful large-animal procedures using its StereoCED platform for drug delivery and electrophysiological monitoring. The company expects to launch human clinical studies this quarter and recognize related revenue in fiscal Q4 2026. The procedures were conducted at the University of Minnesota, demonstrating technical feasibility and validating the integrated surgical and drug delivery workflow.

finanznachrichten.de2 min
AUG 15
Med

NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

NeuroOne Medical Technologies reported Q3 2026 revenue up 16%, driven by demand for its OneRF Brain Ablation System, though recognized revenue was limited by manufacturing lead times. Gross margin rose to 59.9%. Management cited ISO 13485 certification, guidance of $9.2M to $10.5M for FY2026, and a second manufacturing site expected in early 2027.

yahoo.com6 min
AUG 13
$NMTCMed

EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies (Nasdaq: NMTC) reported fiscal Q3 2026 results for the quarter ended June 30, 2026. Product revenue rose 16% YoY to $2.0M and product gross margins expanded to 59.9%. New product orders were $2.7M, lifting backlog to $1.7M, and FY2026 orders totaled $11.2M. The company also cited ISO 13485 certification and updates on StereoCED and OneRF platforms.

finanznachrichten.de7 min
AUG 13
$NMTCMed

NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Wo

SEC EDGAR 8-K6 min